Your Catalyst To a Lucrative Business
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 | Hexa Research
"Type 1 diabetes market size was valued at USD 25.52 billion in 2016 and is expected to exhibit rewarding growth by 2024"
8 November 2018 The global Type 1 Diabetes Market is expected to reach USD 25.52 billion by 2024. A significant increase in the prevalence of type 1 diabetes coupled with Rigorous research & development activities to introduce novel formulations drives the T1D market growth. Sedentary lifestyles, unhealthy diet habits coupled with rising obesity rates will further enhance th e uptake of various types of insulin for the treatment of this disorder. Though this type of diabetes is rare still the number of cases is increasing by 3% every year according to the data enumerated by the International Diabetes Federation (IDF). Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. This affects the respective countries and their national healthcare systems. For instance, the expenditu re on diabetes management accounts for around 5% to 20% of the total healthcare spending. Details of Report @ https://www.hexaresearch.com/research-report/type-1-diabetes-t1d-market
Follow Us:
Your Catalyst To a Lucrative Business Rapid-acting, long-acting and premix analogs are the three major types of insulin analogs administered to the patients. These insulin types when delivered duplicate the action of natural insulin and avoid the excess release of glucose in blood cells. The market penetration of long-acting insulin products is higher as compared to other two types, however, during the forecast period, the uptake and acceptance of rapid an d premix analogs are anticipated to increase. The reason being the quick action and optimum performance of these two over long acting insulin. The insulin analogs market is consolidated in nature as three companies account for more than 50% of the total market share. The reason being extensive product offerings and continuous research and development activities. This market is witnessing an ongoing patent erosion affecting the market sustainability of companies. Also, high probability of launch of several biosimilars by new entrants, major players might face competition during the forecast period. To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly are continuously investing in the development of the improved versions of insulin products. For instance, recent launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version of Lantus). These factors exhibit the promising growth for type 1 diabetes treatment market. Hexa Research has segmented the global type 1 diabetes (T1D) market based on insulin analog, and region: Segmentation by insulin analog, 2014 - 2024 (USD Million) • Rapid acting • Long acting • Premix analogs Segmentation by region, 2014 - 2024 (USD Million) • North America • U.S. • Europe • UK • Asia Pacific • China • India • Rest of the world Key players analyzed • ADOCIA • Biocon • Bioton • Eli Lilly and Company • Novo Nordisk • Sanofi • Wockhardt Browse Related Category Market Reports @ https://www.hexaresearch.com/researchcategory/pharmaceuticals-industry
Follow Us:
Your Catalyst To a Lucrative Business
Table of Content of 3D Scanner Market Chapter 1. Market Summary 1.1. Market trends & movement Chapter 2. Global Type 1 Diabetes (T1D) Market Trends: Drivers & Opportunities 2.1. Introduction 2.2. Market drivers 2.3. Market restraints 2.4. Pipeline analysis 2.5. Novel insulin therapies 2.6. Porter's Five Forces analysis 2.7. SWOT Chapter 3. Global Type 1 Diabetes (T1D) Market Trends, By Insulin Analog 3.1. Global Type 1 Diabetes (T1D) market movement, by Insulin Analog, 2016 & 2024 3.1.1. Rapid Acting Insulin 3.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million) 3.1.2. Long Acting Insulin 3.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million) 3.1.3. Premix Analogs 3.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million) Chapter 4. Global Type 1 Diabetes (T1D) Market Trends, By Region 4.1. Global Type 1 Diabetes (T1D) market movement, by region, 2016 & 2024 4.1.1. North America 4.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.1.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) 4.1.2. Europe 4.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.2.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) 4.1.3. Asia Pacific 4.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.3.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) 4.1.4. Rest of the World (RoW) 4.1.4.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.4.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) Chapter 5. Key Country Markets 5.1. U.S. 5.1.1. Market estimates and forecast, 2014 - 2024 (USD Million) 5.1.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) 5.2. U.K.
Follow Us:
Your Catalyst To a Lucrative Business 5.2.1. Market estimates and forecast, 2014 - 2024 (USD Million) 5.2.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) 5.3. China 5.3.1. Market estimates and forecast, 2014 - 2024 (USD Million) 5.3.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) 5.4. India 5.4.1. Market estimates and forecast, 2014 - 2024 (USD Million) 5.4.2. Market estimates and forecast, by insulin analog, 2014 - 2024 (USD Million) Chapter 6. Competitive Landscape 6.1. Competitive landscape analysis, 2016 6.2. Strategic framework 6.3. Potential customer base concentration 6.4. Company market positioning 6.5. Company profiles 6.5.1. ADOCIA 6.5.1.1. Company Overview 6.5.1.2. Product Benchmarking 6.5.1.3. Financial Performance 6.5.1.4. Recent Initiatives 6.5.2. Biocon 6.5.2.1. Company Overview 6.5.2.2. Product Benchmarking 6.5.2.3. Financial Performance 6.5.2.4. Recent Initiatives 6.5.3. Bioton 6.5.3.1. Company Overview 6.5.3.2. Product Benchmarking 6.5.3.3. Financial Performance 6.5.3.4. Recent Initiatives 6.5.4. Eli Lilly and Company 6.5.4.1. Company Overview 6.5.4.2. Product Benchmarking 6.5.4.3. Financial Performance 6.5.4.4. Recent Initiatives 6.5.5. Novo Nordisk 6.5.5.1. Company Overview 6.5.5.2. Product Benchmarking 6.5.5.3. Financial Performance 6.5.5.4. Recent Initiatives 6.5.6. Sanofi 6.5.6.1. Company Overview 6.5.6.2. Product Benchmarking 6.5.6.3. Financial Performance 6.5.6.4. Recent Initiatives 6.5.7. Wockhardt
Follow Us:
Your Catalyst To a Lucrative Business 6.5.7.1. Company Overview 6.5.7.2. Product Benchmarking 6.5.7.3. Financial Performance 6.5.7.4. Recent Initiatives 6.5.8. List of other vendors Chapter 7. Methodology and Scope 7.1. Research methodology 7.2. Research Scope & Assumptions 7.3. List of data sources
Follow Us:
Your Catalyst To a Lucrative Business
About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email:
[email protected] Website - https://www.hexaresearch.com
Follow Us:
